By Julie Steenhuysen and Nancy Lapid
Feb 21 (Reuters) - A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the SARS-CoV-2 virus that causes COVID-19, raising the possibility that it could someday spread to humans, Chinese researchers have reported.
The virus does not enter human cells as readily as SARS-CoV-2 does, the Chinese researchers reported in the journal Cell, noting some of its limitations.
The scientists said that like SARS-CoV-2, the bat virus HKU5-CoV-2 contains a feature known as the furin cleavage site that helps it to enter cells via the ACE2 receptor protein on cell surfaces.
In lab experiments, HKU5-CoV-2 infected human cells with high ACE2 levels in test tubes and in models of human intestines and airways.
In further experiments, the researchers identified monoclonal antibodies and antiviral drugs that target the bat virus.
Bloomberg, which reported on the study earlier on Friday, said the paper identifying the bat virus had moved shares of COVID vaccine makers. Pfizer PFE.N shares closed up 1.5% on Friday, Moderna MRNA.O climbed 5.3% and Novavax NVAX.O was up about 1% on a down day for the broader market.
Asked about concerns raised by the report of another pandemic resulting from this new virus, Dr. Michael Osterholm, an infectious disease expert at the University of Minnesota, called the reaction to the study "overblown."
He said there is a lot of immunity in the population to similar SARS viruses compared with 2019, which may reduce the pandemic risk.
The study itself noted that the virus has significantly less binding affinity to human ACE2 than SARS-CoV-2, and other suboptimal factors for human adaptation suggest the "risk of emergence in human populations should not be exaggerated."
(Reporting by Julie Steenhuysen and Nancy Lapid; Editing by Caroline Humer and Bill Berkrot)
((Nancy.Lapid@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。